{"id":"mk-4280a","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Immune-mediated adverse events"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CCR4 is highly expressed on regulatory T cells (Tregs) and certain effector T cell populations. By blocking CCR4, MK-4280A prevents these cells from migrating to tumor sites via CCL17 and CCL22 chemokine gradients, thereby reducing immunosuppression in the tumor microenvironment and enhancing anti-tumor immune responses. This mechanism aims to restore anti-tumor immunity and improve checkpoint inhibitor efficacy.","oneSentence":"MK-4280A is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of regulatory T cells and other immune cells to the tumor microenvironment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:44.394Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT06036836","phase":"PHASE2","title":"Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-09-29","conditions":"Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer","enrollment":163},{"nctId":"NCT04938817","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-08-19","conditions":"Small Cell Lung Carcinoma","enrollment":110},{"nctId":"NCT03486873","phase":"PHASE3","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-08-21","conditions":"Solid Tumors, Hematologic Malignancies","enrollment":3500},{"nctId":"NCT04895722","phase":"PHASE2","title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-25","conditions":"Colorectal Cancer","enrollment":302},{"nctId":"NCT04626479","phase":"PHASE1, PHASE2","title":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-16","conditions":"Carcinoma, Renal Cell","enrollment":400},{"nctId":"NCT05508867","phase":"PHASE2","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-10-18","conditions":"Hodgkin Lymphoma","enrollment":203},{"nctId":"NCT05342636","phase":"PHASE1, PHASE2","title":"A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-27","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":90},{"nctId":"NCT05600309","phase":"PHASE3","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-06-14","conditions":"Colorectal Cancer","enrollment":94},{"nctId":"NCT02625961","phase":"PHASE2","title":"Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-02-10","conditions":"Bladder Cancer","enrollment":296},{"nctId":"NCT04303169","phase":"PHASE1, PHASE2","title":"Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-06-26","conditions":"Melanoma","enrollment":146},{"nctId":"NCT05064059","phase":"PHASE3","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-11-10","conditions":"Colorectal Cancer","enrollment":441},{"nctId":"NCT05845814","phase":"PHASE1, PHASE2","title":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-06-23","conditions":"Metastatic Urothelial Carcinoma, Urothelial Neoplasms","enrollment":390},{"nctId":"NCT04305054","phase":"PHASE1, PHASE2","title":"Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-01","conditions":"Melanoma","enrollment":315},{"nctId":"NCT04626518","phase":"PHASE1, PHASE2","title":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-17","conditions":"Carcinoma, Renal Cell","enrollment":370},{"nctId":"NCT02720068","phase":"PHASE1","title":"Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-02","conditions":"Neoplasms","enrollment":481},{"nctId":"NCT06395090","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-15","conditions":"Neoplasm Metastasis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK-4280A","genericName":"MK-4280A","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"MK-4280A is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of regulatory T cells and other immune cells to the tumor microenvironment. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}